Malaria transmission blocking immunity and sexual stage vaccines for interrupting malaria transmission in Latin America

Memorias do Instituto Oswaldo Cruz

Volumn 106, Issue SUPPL. 1, 2011, Pages 202-211

  Arévalo Herrera, Myriam ^a,b,d   Solarte, Yezid ^a   Marin, Catherin ^b   Santos, Mariana ^b   Castellanos, Jenniffer ^b   Beier, John C ^c   Valencia, Sócrates Herrera ^a,b,d  

^a UNIVERSIDAD DEL VALLE   (Colombia)

^b Malaria Vaccine and Drug Development Center   (Colombia)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d Centro Latino Americano de Investigacion en Malaria   (Colombia)

Author keywords

Malaria; Plasmodium; Transmission blocking immunity; Transmission blocking vaccine; Vaccines; Vector borne disease

Indexed keywords

MALARIA VACCINE; PARASITE ANTIGEN; PROTOZOAL PROTEIN; PROTOZOON ANTIBODY;

ANIMAL; HUMAN; IMMUNOLOGY; MALARIA FALCIPARUM; PARASITOLOGY; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM VIVAX MALARIA; REVIEW; SOUTH AND CENTRAL AMERICA;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; HUMANS; LATIN AMERICA; MALARIA VACCINES; MALARIA, FALCIPARUM; MALARIA, VIVAX; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PROTOZOAN PROTEINS;

TULIP BREAKING VIRUS;

EID: 80051766424     PISSN: 00740276     EISSN: 16788060     Source Type: Journal    
DOI: 10.1590/S0074-02762011000900025     Document Type: Review

References (102)

1. Alejo-Blanco AR, Paez A, Gerold P, Dearsly AL, Margos G, Schwardz RT, Barker G, Rodriguez MC, Sinden RE 1999. The biosynthesis and post-translational modification of Pbs21, an ookinete surface protein of Plasmodium berghei. Mol Biochem Parasitol 98: 163-173.
2. Al-Olayan EM, Williams GT, Hurd H 2002. Apoptosis in the malaria protozoan, Plasmodium berghei: a possible mechanism for limiting intensity of infection in the mosquito. Int J Parasitol 32: 1133-1143.
3. Alonso PL, Ballou R, Brown G, Chitnis C, Loucq C, Moorthy V, Saul A, Wirth D 2011a. A research agenda for malaria eradication: vaccines. PLoS Med 8: e1000398.
4. Alonso PL, Brown G, Arevalo-Herrera M, Binka F, Chitnis C, Collins F, Doumbo OK, Greenwood B, Hall BF, Levine MM, Mendis K, Newman RD, Plowe CV, Rodriguez MH, Sinden R, Slutsker L, Tanner M 2011b. A research agenda to underpin malaria eradication. PLoS Med 8: e1000406.
5. Aly AS, Vaughan AM, Kappe SH 2009. Malaria parasite development in the mosquito and infection of the mammalian host. Annu Rev Microbiol 63: 195-221.
6. Arevalo-Herrera M, Castellanos A, Yazdani SS, Shakri AR, Chitnis CE, Dominik R, Herrera S 2005a. Immunogenicity and protective efficacy of recombinant vaccine based on the receptor-binding domain of the Plasmodium vivax Duffy binding protein in Aotus monkeys. Am J Trop Med Hyg 73: 25-31.
7. Arevalo-Herrera M, Solarte Y, Rocha L, Alvarez D, Beier JC, Herrera S 2011. Characterization of Plasmodium vivax transmission-blocking activity in low to moderate malaria transmission settings of the Colombian Pacific coast. Am J Trop Med Hyg 84: 71-77.
8. Arevalo-Herrera M, Solarte Y, Yasnot MF, Castellanos A, Rincon A, Saul A, Mu J, Long C, Miller L, Herrera S 2005b. Induction of transmission-blocking immunity in Aotus monkeys by vaccination with a Plasmodium vivax clinical grade Pvs25 recombinant protein. Am J Trop Med Hyg 73: 32-37.
9. Arevalo-Herrera M, Solarte Y, Zamora F, Mendez F, Yasnot MF, Rocha L, Long C, Miller LH, Herrera S 2005c. Plasmodium vivax: transmission-blocking immunity in a malaria-endemic area of Colombia. Am J Trop Med Hyg 73: 38-43.
10. Boudin C, Diop A, Gaye A, Gadiaga L, Gouagna C, Safeukui I, Bonnet S 2005. Plasmodium falciparum transmission blocking immunity in three areas with perennial or seasonal endemicity and different levels of transmission. Am J Trop Med Hyg 73: 1090-1095.
11. Boudin C, Van Der Kolk M, Tchuinkam T, Gouagna C, Bonnet S, Safeukui I, Mulder B, Meunier JY, Verhave JP 2004. Plasmodium falciparum transmission blocking immunity under conditions of low and high endemicity in Cameroon. Parasite Immunol 26: 105-110.
12. Bousema T, Roeffen W, Meijerink H, Mwerinde H, Mwakalinga S, van Gemert GJ, van de Vegte-Bolmer M, Mosha F, Targett G, Riley EM, Sauerwein R, Drakeley C 2010. The dynamics of naturally acquired immune responses to Plasmodium falciparum sexual stage antigens Pfs230 & Pfs48/45 in a low endemic area in Tanzania. PLoS ONE 5: e14114.
13. Bousema T, Sutherland CJ, Churcher TS, Mulder B, Gouagna LC, Riley EM, Targett GA, Drakeley CJ 2011. Human immune responses that reduce the transmission of Plasmodium falciparum in African populations. Int J Parasitol 41: 293-300.
14. Cao YM, Tsuboi T, Torii M 1998. Nitric oxide inhibits the development of Plasmodium yoelii gametocytes into gametes. Parasitol Int 47: 157-166.
15. Carter R 2001. Transmission blocking malaria vaccines. Vaccine 19: 2309-2314.
16. Carter R, Graves P, Keister DB, Quakyi I 1990. Properties of epitopes of Pfs48/45, a target of transmission blocking monoclonal antibodies, on gametes of different isolates of Plasmodium falciparum. Parasit Immunol 12: 587-603.
17. Carter R, Mendis K 1992. Transmission immunity in malaria: reflections on the underlying immune mechanisms during natural infections and following artificial immunization. Mem Inst Oswaldo Cruz 87 (Suppl. III): 169-173.
18. Carter R, Mendis KN, Miller LH, Molineaux L, Saul A 2000. Malaria transmission-blocking vaccines-how can their development be supported? Nat Med 6: 241-244.
19. Chowdhury DR, Angov E, Kariuki T, Kumar N 2009. A potent malaria transmission blocking vaccine based on codon harmonized full length Pfs48/45 expressed in Escherichia coli. PLoS ONE 4: e6352.
20. Collins WE, Barnwell JW, Sullivan JS, Nace D, Williams T, Bounngaseng A, Roberts J, Strobert E, McClure H, Saul A, Long CA 2006. Assessment of transmission-blocking activity of candidate Pvs25 vaccine using gametocytes from chimpanzees. Am J Trop Med Hyg 74: 215-221.
21. Colombatti A, Bonaldo P, Dolian R 1993. Type A modules: interacting domains found in several non-fibrillar collagens and in other extracellular matrix proteins. Matrix 13: 297-306.
22. Coutinho-Abreu IV, Ramalho-Ortigao M 2010. Transmission blocking vaccines to control insect-borne diseases - A Review. Mem Inst Oswaldo Cruz 105: 1-12.
23. Dawes EJ, Churcher TS, Zhuang S, Sinden RE, Basanez MG 2009. Anopheles mortality is both age- and Plasmodium-density dependent: implications for malaria transmission. Malar J 8: 228.
24. Dinglasan RR, Kalume DE, Kanzok SM, Ghosh AK, Muratova O, Pandey A, Jacobs-Lorena M 2007. Disruption of Plasmodium falciparum development by antibodies against a conserved mosquito midgut antigen. Proc Natl Acad Sci USA 104: 13461-13466.
25. Doi M, Tanabe K, Tachibana S, Hamai M, Tachibana M, Mita T, Yagi M, Zeyrek FY, Ferreira MU, Ohmae H, Kaneko A, Randrianarivelojosia M, Sattabongkot J, Cao YM, Horii T, Torii M, Tsuboi T 2011. Worldwide sequence conservation of transmission-blocking vaccine candidate Pvs230 in Plasmodium vivax. Vaccine 29: 4308-4315.
26. Doolan DL, Hoffman SL 2001. DNA-based vaccines against malaria: status and promise of the Multi-Stage Malaria DNA Vaccine Operation. Int J Parasitol 31: 753-762.
27. Eksi S, Czesny B, van Gemert GJ, Sauerwein RW, Eling W, Williamson KC 2006. Malaria transmission-blocking antigen, Pfs230, mediates human red blood cell binding to exflagellating male parasites and oocyst production. Mol Microbiol 61: 991-998.
28. Fanning SL, Czesny B, Sedegah M, Carucci DJ, G-J G, Eling W, Williamson KC 2003. A glycosylphosphatidylinositol anchor signal sequence enhances the immunogenicity of a DNA vaccine encoding Plasmodium falciparum sexual-stage antigen, Pfs230. Vaccine 21: 3228-3225.
29. Feachem RG, Phillips AA 2009. Malaria: 2 years in the fast lane. Lancet 373: 1409-1411.
30. Florens L, Washburn MP, Raine JD, Anthony RM, Grainger M, Haynes JD, Moch JK, Muster N, Sacci JB, Tabb DL, Witney AA, Wolters D, Wu Y, Gardner MJ, Holder AA, Sinden RE, Yates JR, Carucci DJ 2002. A proteomic view of the Plasmodium falciparum life cycle. Nature 419: 520-526.
31. Foo A, Carter R, Lambros C, Graves P, Quakyi I, Targett GTA, Ponnudurai T, Lewis GE 1991. Conserved and variant epitopes of target antigens of transmission-blocking antibodies among isolates of Plasmodium falciparum from Malaysia. Am J Trop Med Hyg 44: 623-631.
32. Gamage-Mendis AC, Rajakaruna J, Carter R, Mendis KN 1992. Transmission blocking immunity to human Plasmodium vivax malaria in an endemic population in Kataragama, Sri Lanka. Parasit Immunol 14: 385-396.
33. Genton B, D'Acremont V, Rare L, Baea K, Reeder JC, Alpers MP, Muller I 2008. Plasmodium vivax and mixed infections are associated with severe malaria in children: a prospective cohort study from Papua New Guinea. PLoS Med 5: e127.
34. Gholizadeh S, Djadid ND, Basseri HR, Zakeri S, Ladoni H 2009. Analysis of von Willebrand factor A domain-related protein (WARP) polymorphism in temperate and tropical Plasmodium vivax field isolates. Malar J 8: 137.
35. Ghosh A, Edwards MJ, Jacobs-Lorena M 2000. The journey of the malaria parasite in the mosquito: hopes for the new century. Parasitol Today 16: 196-201.
36. Ghosh AK, Ribolla PE, Jacobs-Lorena M 2001. Targeting Plasmodium ligands on mosquito salivary glands and midgut with a phage display peptide library. Proc Natl Acad Sci USA 98: 13278-13281.
37. Girard MP, Reed ZH, Friede M, Kieny MP 2007. A review of human vaccine research and development: malaria. Vaccine 25: 1567-1580.
38. Greenwood BM, Bojang K, Whitty CJ, Targett GA 2005. Malaria. Lancet 365: 1487-1498.
39. Greenwood BM, Fidock DA, Kyle DE, Kappe SH, Alonso PL, Collins FH, Duffy PE 2008. Malaria: progress, perils, and prospects for eradication. J Clin Invest 118: 1266-1276.
40. Grotendorst CA, Carter R 1987. Complement effects of the infectivity of Plasmodium gallinaceum to Aedes aegypti mosquitoes. II. Changes in sensitivity to complement-like factors during zygote development. J Parasitol 73: 980-984.
41. Grotendorst CA, Carter R, Rosenberg R, Koontz LC 1986. Complement effects on the infectivity of Plasmodium gallinaceum to Aedes aegypti mosquitoes. I. Resistance of zygotes to the alternative pathway of complement. J Immunol 136: 4270-4274.
42. Guerra CA, Gikandi PW, Tatem AJ, Noor AM, Smith DL, Hay SI, Snow RW 2008. The limits and intensity of Plasmodium falciparum transmission: implications for malaria control and elimination worldwide. PLoS Med 5: e38.
43. Haddad D, Maciel J, Kumar N 2006. Infection with Plasmodium berghei boosts antibody responses primed by a DNA vaccine encoding gametocyte antigen Pbs48/45. Infect Immun 74: 2043-2051.
44. Healer J, McGuinness D, Carter R, Riley E 1999. Transmission-blocking immunity to Plasmodium falciparum in malaria-immune individuals is associated with antibodies to the gamete surface protein Pfs230. Parasitology 119: 425-433.
45. Herrera S, Rodriguez D, Acero D, Ocampo V, Arévalo-Herrera M 2011. Platform for Plasmodium vivax vaccine discovery and development. Mem Inst Oswaldo Cruz 106 (Suppl. I): 179-192.
46. Hisaeda H, Stowers AW, Tsuboi T, Collins WE, Sattabongkot JS, Suwanabun N, Torii M, Kaslow DC 2000. Antibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of Plasmodium vivax to infect mosquitoes. Infect Immun 68: 6618-6623.
47. Hisaeda H, Yasutomo K 2002. Development of malaria vaccines that block transmission of parasites by mosquito vectors. J Med Invest 49: 118-123.
48. Kaslow DC 1990. Immunogenicity of Plasmodium falciparum sexual stage antigens: implications for the design of a transmission blocking vaccine. Immunol Lett 25: 83-86.
49. Kaslow DC 1996. Transmission blocking vaccines. In SL Hofman (ed.), Malaria vaccine development, ASM Press, Washington, p. 181-228.
50. Kaslow DC, Bathurst IC, Barr PJ 1992. Malaria transmission-blocking vaccines. Tibtech 10: 388-391.
51. Kaslow DC, Bathurst IC, Lensen T, Ponnudurai T, Barr PJ, Keister DB 1994. Saccharomyces cerevisiae recombinant Pfs25 adsorbed to alum elicits antibodies that block transmission of Plasmodium falciparum. Infect Immun 62: 5576-5580.
52. Kaslow DC, Quakyi IA, Syin C, Raum MG, Keister DB, Coligan JE, McCutchan TF, Miller LH 1988. A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains. Nature 333: 74-76.
53. Kaslow DC, Shiloach J 1994. Production, purification and immunogenicity of a malaria transmission-blocking vaccine candidate: TBV25H expressed in yeast and purified using nickel-NTA agarose. Biotech 12: 494-499.
54. Kelly-Hope L, Ranson H, Hemingway J 2008. Lessons from the past: managing insecticide resistance in malaria control and eradication programmes. Lancet Infect Dis 8: 387-389.
55. Kocken CH, Jansen J, Kaan AM, Beckers PJ, Ponnudurai T, Kaslow DC, Konings RN, Schoenmakers JG 1993. Cloning and expression of the gene coding for the transmission blocking target antigen Pfs48/45 of Plasmodium falciparum. Mol Biochem Parasitol 61: 59-68.
56. Kumar N, Carter R 1984. Biosynthesis of the target antigens of antibodies blocking transmission of Plasmodium falciparum. Mol Biochem Parasitol 13: 333-342.
57. Kumar S, Christophides GK, Cantera R, Charles B, Han YS, Meister S, Dimopoulos G, Kafatos FC, Barillas-Mury C 2003. The role of reactive oxygen species on Plasmodium melanotic encapsulation in Anopheles gambiae. Proc Natl Acad Sci USA 100: 14139-14144.
58. Lal AA, Patterson PS, Sacci JB, Vaughan JA, Paul C, Collins WE, Wirtz RA, Azad AF 2001. Anti-mosquito midgut antibodies block development of Plasmodium falciparum and Plasmodium vivax in multiple species of Anopheles mosquitoes and reduce vector fecundity and survivorship. Proc Natl Acad Sci 98: 5228-5233.
59. Lavazec C, Bourgouin C 2008. Mosquito-based transmission blocking vaccines for interrupting Plasmodium development. Microbes Infect 10: 845-849.
60. Lee JO, Rieu P, Arnaout MA, Liddington R 1995. Crystal structure of the A domain from the alpha subunit of integrin CR3 (CD11b/CD18). Cell 80: 631-638.
61. Lobo CA, Dhar R, Kumar N 1999. Immunization of mice with DNA-based Pfs25 elicits potent malaria transmission-blocking antibodies. Infect Immun 67: 1688-1693.
62. Luckhart S, Vodovotz Y, Cui L, Rosenberg R 1998. The mosquito Ano-pheles stephensi limits malaria parasite development with inducible synthesis of nitric oxide. Proc Natl Acad Sci 95: 5700-5705.
63. Malkin EM, Durbin AP, Diemert DJ, Sattabongkot J, Wu Y, Miura K, Long CA, Lambert L, Miles AP, Wang J, Stowers A, Miller LH, Saul A 2003. Phase I trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. Vaccine 23: 3131-3138.
64. McDonnell WM, Askari FK 1996. DNA vaccines. N Engl J Med 334: 42-45.
65. Mendis C, Munesinghe YD, de Silva YNY, Keragalla I, Carter R 1987. Malaria transmission-blocking immunity induced by natural infections of Plasmodium vivax in humans. Infect Immun 55: 369-372.
66. Mendis KN, David PH, Carter R 1991. Antigenic polymorphism in malaria: is it an important mechanism for immune evasion? Immunol Today 12: A34-37.
67. Milek RL, Roeffen WF, Kocken CH, Jansen J, Kaan AM, Eling WM, Sauerwein RW, Konings RN 1998. Immunological properties of recombinant proteins of the transmission blocking vaccine candidate, Pfs48/45, of the human malaria parasite Plasmodium falciparum produced in Escherichia coli. Parasit Immunol 20: 377-385.
68. Miyata T, Harakuni T, Sugawa H, Sattabongkot J, Kato A, Tachibana M, Torii M, Tsuboi T, Arakawa T 2011. Adenovirus-vectored Plasmodium vivax ookinete surface protein, Pvs25, as a potential transmission-blocking vaccine. Vaccine 29: 2720-2726.
69. Moorthy VS, Good MF, Hill AV 2004. Malaria vaccine developments. Lancet 363: 150-156.
70. Moreira CK, Marrelli MT, Jacobs-Lorena M 2004. Gene expression in Plasmodium: from gametocytes to sporozoites. Int J Parasitol 34: 1431-1440.
71. Mulder B, Lensen T, Tchuinkam T, Roeffen W, Verhave JP, Boudin C, Sauerwein R 1999. Plasmodium falciparum: membrane feeding assays and competition ELISAs for the measurement of transmission reduction in sera from Cameroon. Exp Parasitol 92: 81-86.
72. Naotunne TdS, Karunaweera N, Mendis KN, Carter R 1993. Cytokine-mediated inactivation of malarial gametocytes is dependent on the presence of white cells. Immunol 78: 555-562.
73. Naotunne TS, Karunaweera ND, Del Giudice G, Kularatne MU, Grau GE, Carter R, Mendis KN 1991. Cytokines kill malaria parasites during infection crisis: extracellular complementary factors are essential. J Exp Med 173: 523-529.
74. Outchkourov NS, Roeffen W, Kaan A, Jansen J, Luty A, Schuiffel D, van Gemert GJ, van de Vegte-Bolmer M, Sauerwein RW, Stunnenberg HG 2008. Correctly folded Pfs48/45 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in mice. Proc Natl Acad Sci USA 105: 4301-4305.
75. Peiris JS, Premawansa S, Ranawaka MB, Udagama PV, Munasinghe YD, Nanayakkara MV, Gamage CP, Carter R, David PH, Mendis KN 1988. Monoclonal and polyclonal antibodies both block and enhance transmission of human Plasmodium vivax malaria. Am J Trop Med Hyg 39: 26-32.
76. Premawansa S, Gamage-Mendis A, Perera L, Begarnie S, Mendis K, Carter R 1994. Plasmodium falciparum malaria transmission-blocking immunity under conditions of low endemicity as in Sri Lanka. Parasite Immunol 16: 35-42.
77. Quakyi IA, Carter R, Rener J, Kumar N, Good MF, Miller LH 1987. The 230-kDa gamete surface protein of Plasmodium falciparum is also a target for transmission-blocking antibodies. J Immunol 139: 4213-4217.
78. Ramsey JM, Salinas E, Rodriguez MH 1996. Acquired transmission-blocking immunity to Plasmodium vivax in a population of southern coastal Mexico. Am J Trop Med Hyg 54: 458-463.
79. Ranawaka MB, Munesinghe YD, da Silva DMR, Carter R, Mendis KN 1988. Boosting of transmission blocking immunity during natural Plasmodium vivax infection in humans depends upon frequent reinfection. Infect Immun 56: 1820-1824.
80. Read D, Lensen AH, Begarnies S, Haley S, Raza A, Carter R 1994. Transmission-blocking antibodies against multiple, non-variant target epitopes of the Plasmodium falciparum gamete surface antigen Pfs230 are all complement-fixing. Parasit Immunol 16: 511-519.
81. Reed ZH, Friede M, Kieny MP 2006. Malaria vaccine development: progress and challenges. Curr Mol Med 6: 231-245.
82. Richie TL, Saul A 2002. Progress and challenges for malaria vaccines. Nature 415: 694-701.
83. Roeffen W, Beckers PJA, Tecien K, Lensen T, Sauerwein RW, Meuwissen JHET, Eling W 1995. Plasmodium falciparum: a comparison of the activity of Pfs230-specific antibodies in an assay of transmission-blocking immunity and specific competition ELISAs. Exp Parasitol 80: 15-26.
84. Sattabongkot J, Tsuboi T, Zollner GE, Sirichaisinthop J, Cui L 2004. Plasmodium vivax transmission: chances for control? Trends Parasitol 20: 192-198.
85. Sinden RE 2010. A biologist's perspective on malaria vaccine development. Hum Vaccin 6: 3-11.
86. Smith TA, Chitnis N, Briet OJ, Tanner M 2011. Uses of mosquito-stage transmission-blocking vaccines against Plasmodium falciparum. Trends Parasitol 27: 190-196.
87. Snounou G 2004. Cross-species regulation of Plasmodium parasitaemia cross-examined. Trends Parasitol 20: 262-265.
88. Solarte Y, Manzano MR, Rocha L, Hurtado H, James MA, Arevalo-Herrera M, Herrera S 2011. Plasmodium vivax sporozoite production in Anopheles albimanus mosquitoes for vaccine clinical trials. Am J Trop Med Hyg 84: 28-34.
89. Stowers A, Carter R 2001. Current developments in malaria transmission-blocking vaccines. Expert Opin Biol Ther 1: 619-628.
90. Sutherland CJ 2009. Surface antigens of Plasmodium falciparum gametocytes: a new class of transmission-blocking vaccine targets? Mol Biochem Parasitol 166: 93-98.
91. Targett GA, Greenwood BM 2008. Malaria vaccines and their potential role in the elimination of malaria. Malar J 7 (Suppl. 1): S10.
92. Touray MG, Seeley DC, Jr., Miller LH 1994. Plasmodium gallinaceum: differential lysis of two developmental stages of malaria sporozoites by the alternative pathway of complement. Exp Parasitol 78: 294-301.
93. Tsuboi T, Kaslow DC, Gozar MM, Tachibana M, Cao YM, Torii M 1998. Sequence polymorphism in two novel Plasmodium vivax ookinete surface proteins, Pvs25 and Pvs28, that are malaria transmission-blocking vaccine candidates. Mol Med 4: 772-782.
94. Tsuboi T, Tachibana M, Kaneko O, Torii M 2003. Transmission-blocking vaccine of Plasmodium vivax malaria. Parasitol Int 52: 1-11.
95. van der Kolk M, De Vlas SJ, Saul A, van de Vegte-Bolmer M, Eling WM, Sauerwein RW 2005. Evaluation of the standard membrane feeding assay (SMFA) for the determination of malaria transmission-reducing activity using empirical data. Parasitology 130: 13-22.
96. van Dijk MR, Janse CJ, Thompson J, Waters AP, Braks JA, Dodemont HJ, Stunnenberg HG, van Gemert GJ, Sauerwein RW, Eling W 2001. A central role for P48/45 in malaria parasite male gamete fertility. Cell 104: 153-164.
97. Vinetz JM, Valenzuela JG, Specht CA, Aravind L, Langer RC, Ribeiro JM, Kaslow DC 2000. Chitinases of the avian malaria parasite Plasmodium gallinaceum, a class of enzymes necessary for parasite invasion of the mosquito midgut. J Biol Chem 275: 10331-10341.
98. WHO - World Health Organization 2010. World malaria report, WHO, Geneva, Available from: who.int/malaria/world_malaria_report_2010/en/index.html.
99. Wu Y, Ellis RD, Shaffer D, Fontes E, Malkin EM, Mahanty S, Fay MP, Narum D, Rausch K, Miles AP, Aebig J, Orcutt A, Muratova O, Song G, Lambert L, Zhu D, Miura K, Long C, Saul A, Miller LH, Durbin AP 2008. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS ONE 3: e2636.
100. Wu Y, Przysiecki C, Flanagan E, Bello-Irizarry SN, Ionescu R, Muratova O, Dobrescu G, Lambert L, Keister D, Rippeon Y, Long CA, Shi L, Caulfield M, Shaw A, Saul A, Shiver J, Miller LH 2006. Sustained high-titer antibody responses induced by conjugating a malarial vaccine candidate to outer-membrane protein complex. Proc Natl Acad Sci USA 103: 18243-18248.
101. Wykes M, Good MF 2007. A case for whole-parasite malaria vaccines. Int J Parasitol 37: 705-712.
102. Yuda M, Yano K, Tsuboi T, Torii M, Chinzei Y 2001. von Willebrand factor A domain-related protein, a novel microneme protein of the malaria ookinete highly conserved throughout Plasmodium parasites. Mol Biochem Parasitol 116: 65-72.